The y-aminobutyric acid antagonist, bicuculline methiodide (BMI), induces myoclonic seizures in rats when injected into the deep prepyriform cortex at concentrations lower than those that induce convulsions from the amygdala, hippocampus, or neocortex. This observation prompted the suggestion that the deep prepyriform cortex was responsible for seizure generation regardless of the neurotransmitter and neuronal circuits involved. Bilateral intrastriatal application of BMI protects rats against seizures induced by (i) local application of BMI into the deep prepyriform cortex and (ii) systemic application of bicuculline, pilocarpine (a cholinergic agonist), or kainic acid (a glutamate receptor agonist). The region of the striatum sensitive to the previously unknown anticonvulsant action of BMI is located in the immediate vicinity of the deep prepyriform cortex and is 100-150 times more sensitive to the anticonvulsant action relative to the sensitivity of the deep prepyriform cortex to the convulsant action of BMI. These data suggest a powerful y-aminobutyric acid-dependent gating role of the basal ganglia in determining the seizure threshold in the forebrain. This argues against the suggestion that the deep prepyriform cortex plays a crucial role in the generation of seizures following systemic administration of convulsants. The discovery of an anticonvulsant action of BMI in the rat striatum contradicts the r-aminobutyric acid theory of epilepsy, which implies that deficits in the yaminobutyric acid-mediated inhibition in the central nervous system lead to the emergence of seizures.
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The search for morphological substrates of seizures in the brain has been the major goal of epilepsy research over the last three decades. The function of the basal ganglia in the spread of seizures has received considerable attention since the discovery of anticonvulsant activity ofdrugs that enhance y-aminobutyric acid (GABA)-mediated inhibition in the substantia nigra (1) . The entopeduncular nucleus has been subsequently identified as another site where GABA agonists act to block seizures (2) . The anatomical background for these actions was the finding that pathways linking the striatum and either substantia nigra or entopeduncular nucleus regulate the seizure threshold in the forebrain (3) .
Clinical studies in humans and lesion studies in primates and rodents have described a role for the striatum in determining seizure threshold (3) (4) (5) . However, the actions and interactions of different striatal transmitters possibly involved in modulating seizure spread have not been identified. We recently discovered that microinjections of nanomole amounts of the excitatory amino acid N-methyl-D-aspartate into the striatum of rats suppressed amygdala kindling (6) and pilocarpine-induced seizures (3) . The anticonvulsant action of N-methyl-D-aspartate in the striatum was reversed by blocking GABA-mediated inhibition in the substantia nigra pars reticulata or in the entopeduncular nucleus (3). This finding suggested that activation of striatal GABAergic efferent pathways may induce an anticonvulsant action.
GABA is reported to be localized in striatal interneurons or in collaterals of striatal output neurons (7) . The GABAergic interneurons innervate GABA-containing efferent pathways (8) and regulate the activity of striatal output neurons (9) . Thus, the inference emerges that a GABA/GABA balance in the striatum participates in the fine regulation of the seizure threshold in the forebrain.
The deep prepyriform cortex is believed to subserve a triggering function for different types of convulsions and may be crucial to the generation of convulsant-induced seizures (10) . Therefore, we have compared the convulsant actions of bicuculline methiodide (BMI) following its application into the deep prepyriform cortex with its anticonvulsant actions after bilateral microinjections into the rat striatum.
MATERIALS AND METHODS
The subjects were male Wistar rats weighing 250-300 g. The rats were anesthetized i.p. with sodium pentobarbital (Nembutal; Ceva, Watford, U.K.; 50 mg/kg) and implanted with guide cannulae directed towards the deep prepyriform cortex or the striatum. The microinjections were made in the frontal plane at AP +4.0 (11), which corresponds to the anatomical definition of sites in the deep prepyriform cortex sensitive to the convulsant action of BMI (10) . The microinjections into the deep prepyriform cortex and striatum were performed bilaterally in unanesthetized rats. No rats were used for more than one pair of injections. Drugs were delivered into the deep prepyriform cortex and striatum in a volume of 0.25 ,ul at a rate of 0.1 Al/min. BMI (Pierce) was administered into the deep prepyriform cortex in doses of 10, 20, 50, and 100 pmol and into the striatum in doses of 0.1, 0.2, 0.5, and 1 pmol. The microinjections of BMI in the striatum were followed 15 min later by i.p. injection of bicuculline (4 mg/kg). BMI in the dose of 1 pmol was also administered into the striatum 15 min before microinjection of BMI (100 pmol) into the deep prepyriform cortex, pilocarpine hydrochloride (Sigma; 380 mg/kg, i.p.) or kainic acid (Sigma; 12 mg/kg, i.p.). Methylscopolamine nitrate (Sigma; 1 mg/kg) was administered s.c. 30 min before injection of pilocarpine to limit peripheral toxic effects (3). (Fig. 1) Fig. 2 ). Electroencephalographic monitoring showed that microinjection of BMI into the striatum suppressed the generation of seizures in the cortex and hippocampus after BMI injection into the deep prepyriform cortex. Microinjection of saline into the striatum did not affect the convulsant action of BMI in the deep prepyriform cortex (5/5) ( Table 1) .
BMI (1 pmol) injected into the striatum was also anticonvulsant in rats subjected 15 min later to systemic injection of pilocarpine, 380 mg/kg (0/5) or kainic acid, 12 mg/kg (0/5) ( Table 1) . Electroencephalographic monitoring and morphological analysis revealed neither seizure activity in the hippocampus and cortex nor seizure-related brain damage typically observed in rats receiving saline in the striatum and then pilocarpine or kainic acid.
DISCUSSION
BMI is 20-50 times more potent as a convulsant in the deep prepyriform cortex than in the amygdala or hippocampus (10, 13) . This high sensitivity of the deep prepyriform cortex was used as evidence for Piredda and Gale (10) to suggest this region was the site from which seizures are generated after systemic administration of convulsants. However, their experimental protocol did not extend to the paradoxical anticonvulsant activity of bicuculline reported here. A clear-cut anticonvulsant activity of BMI in the striatum in four different experimental models of epilepsy presented in this study
shows that the view of Piredda and Gale (10) does not apply to the focal application of chemoconvulsants into the brain.
The data presented here show that convulsions induced by BMI injection into the deep prepyriform cortex are blocked by BMI injection into the striatum. The doses of striatal BMI required to block seizures induced by BMI injected into the deep prepyriform cortex are =100 times lower than those that elicit convulsions in rats treated with saline in the striatum. If the argument of sensitivity is predictive for delineation of the primary convulsant site in the brain, then our observations contradict those of Piredda and Gale (10) A high anticonvulsant potential of BMI in the striatum suggests that GABA in this region regulates seizure threshold by acting as a gate allowing or disallowing activity changes in sets of output neurons. Electrophysiological analysis of striatonigral and striatoentopeduncular pathways shows that decreases in the GABAergic activity in the striatum increases GABAergic activity in the substantia nigra and entopeduncular nucleus (9) . This implies that deficits in the GABA-mediated inhibition in the striatum induced by microinjection of BMI disinhibits GABA-mediated output pathways and enhances net inhibition in their respective targets, e.g. substantia nigra, pars reticulata, and entopeduncular nucleus. Previous microinjection studies have shown an anticonvulsant potential for the GABA agonist muscimol and GABA transaminase inhibitor yvinyl-GABA in the substantia nigra, pars reticulata, and entopeduncular nucleus in several seizure models in rodents (1, 3, 14) . This may explain why BMI acting as a GABA antagonist is "paradoxically" anticonvulsant in the striatum.
Although several attempts to understand mechanisms of epileptogenesis have been made, no satisfactory unifying theory has yet been advanced within which pathological phenomena underlying epilepsy can be understood. The epileptology. This theory arose from observations that (i) drugs that impair GABAergic transmission induce overt convulsions, whereas those that enhance GABAergic transmission are anticonvulsant; (ii) impairment of GABAergic transmission contributes to experimental seizures; (iii) GABAergic transmission in discrete brain regions modulates propagation of seizures; and (iv) GABAergic transmission is impaired in human epilepsy (16, 17) . This theory attempts to explain the mechanism of generation of seizures and the mechanism of action of several anticonvulsant drugs (16) . According to this theory deficits in GABA-mediated inhibition are sufficient for the emergence of seizures (15, 17) .
Our studies provide evidence that impairment of GABAmediated inhibition in the striatum is anticonvulsant in four different seizure models. This finding shows that a deficiency in GABAergic transmission is not a sufficient prerequisite of seizures and argues against the overall validity of the GABA theory of epilepsy. This finding explicitly demonstrates that the GABA theory does not apply to the entire brain. Further research will expand our knowledge of the morphological structures and neuronal networks mediating the excitation/ inhibition balance regulating seizure spread. In the meantime we may arrive at new interpretations of the functional role of GABA in epilepsy.
